BrainsWay deep transcranial magnetic stimulation (dTMS) therapy provides patients with major depressive disorder (MDD) or treatment resistant depression (TRD) with a powerful treatment option that is more effective than pharmacotherapy alone. Although TMS treatment displays better patient outcomes than traditional antidepressant medications, not all TMS treatments are created equal. In fact, a 2019 study of 288 MDD patients revealed significant differences in treatment efficacy of deep TMS (dTMS) in comparison to repetitive TMS (rTMS).
In the study, MDD patients undergoing pharmacotherapy either received deep transcranial magnetic stimulation (dTMS) therapy, or repetitive transcranial magnetic stimulation(rTMS) therapy in addition to their medication routine, or were treated exclusively with pharmacotherapy. After four weeks of TMS treatment (a total of 20 treatments), patients were evaluated based on the severity of their depressive symptoms. Complete symptom remission was defined as scoring 7 or less on the Hamilton Depression Rating Scale (HAM-D),which is considered “normal”.
Key findings from the study included:
- The remission rate of MDD patients who received dTMS therapy or rTMS therapy was higher than the remission rate of patients who were treated exclusively with pharmacotherapy.
- 59.7% of patients in the dTMS group achieved complete remission from their depressive symptoms, compared to 42.7% of patients in the rTMS group.
- The HAM-D score of patients who received dTMS therapy was lowered by 59%, while the HAM-D score of patients who received rTMS therapy was lowered by 41%.
The study also confirmed the safety and efficacy of dTMS and rTMS therapies as adjunctive treatments of MDD. Therefore, patients who take antidepressant medications, but are not seeing adequate symptom relief may finally find improved quality of life and symptom reduction by adding dTMS or rTMS to their existing treatment program.
A Closer Look at rTMS versus dTMS
Repetitive or rTMS and dTMS therapy both involve the use of magnetic pulses to stimulate nerve cells in areas of the brain that are responsible for mood regulation. Both rTMS and dTMS are used to treat severe depression, and require a series of treatment sessions to deliver optimal results. A typical TMS therapy program involves five sessions per week conducted over the course of six weeks, with each treatment session lasting about 20 minutes.
Deep TMS represents the next evolution of TMS therapy. Like rTMS, dTMS involves the use of magnetic fields that stimulate neurons in the brain to treat depression. However, dTMS stimulates a larger volume of gray matter in the left dorsolateral prefrontal cortex (LDPFC) in comparison to rTMS. It also delivers a deeper and broader magnetic field in contrast to rTMS, which results in more significant symptom reduction, as evidenced by this study. Remember, 59.7% of dTMS patients achieved complete remission from their depressive symptoms, compared to 42.7% of rTMS patients.
Advantages of Deep TMS in Treating Major Depressive Disorder
Deep TMS (dTMS) therapy revolutionizes the treatment of depression, as it is designed for patients who failed to respond to antidepressant medications.
It has been proven to help patients dealing with refractory or treatment resistant depression regain a sense of wellbeing and improve their quality of life. The advantages of deep TMS include:
- Short Treatments: dTMS involves sitting in a chair and wearing a helmet that features a patented H-coil for 20 minutes. The coil creates a temporary magnetic field that stimulates the brain to help treat depression.
- FDA-Approved: The BrainsWay dTMS device has been FDA-approved for treatment of depression and OCD. Additionally, BrainsWay’s TMS technology has been tested in over 60 clinical trials worldwide and can help patients with clinical depression who have not responded well to medications or a combination of psychotherapy and medication.
- No Hospitalization Required: dTMStherapy is performed as a painless, noninvasive outpatient procedure. It does not require hospitalization or anesthesia, and patients can resume all daily activities immediately after each session
BrainsWay dTMS technology is FDA-approved to treat OCD and depression. It is also CE- and ANIVISA-approved to treat the following conditions:
- Bipolar disorder
- Chronic pain
- Parkinson’s disease
BrainsWay has also been CE-approved to treat Alzheimer’s disease, autism, and multiple sclerosis.
Is BrainsWay dTMS Therapy Right for You?
To qualify for dTMS therapy insurance coverage, an individual dealing with a mental health condition must meet requirements defined by his or her insurance provider. Many insurance providers offer dTMS therapy coverage for MDD based on the following criteria:
- A patient is dealing with an ongoing depressive episode and
- Within the aforementioned depressive episode
The patient must provide the name and approximate dates of antidepressants taken and results of each trial
- The patient must have no contraindications for TMS therapy, including no suicidal ideation, psychotic symptoms, metal in the cranium, and neurological conditions (seizures). Patients who are pregnant, nursing, or dealing with substance abuse issues do not qualify for BrainsWay dTMS therapy.
At Achieve TMS, we providedTMS therapy for Major Depressive Disorder, Treatment Resistant and Refractory Depression, and Obsessive-Compulsive Disorder.. Our expert medical team meets with patients to discuss TMS, how it works, and its advantages. We also respond to patients’ concerns and questions to ensure they know exactly what to expect during a TMS therapy program.
The Achieve TMS team is happy to meet with a patient to determine if he or she qualifies for TMS therapy. To schedule a free TMS therapy consultation with Achieve TMS, contact us online or you can call or text us at 877-871-6379.